Jagsonpal Pharmaceuticals Limited

rs,

January 22, 2025 The Department of Corporate Services- Listing BSE Ltd, Phiroze Jeejeebhoy Towers, Dalal Street Mumbai-400 001 Scrip Code: 507789 The Department of Corporate Services- Listing Na

₹740

Jagsonpal Pharmaceuticals announces Q3FY25 and 9MFY25 Results Q3FY25 Revenue at ₹740 Mn, 57% growth over Q3FY24 Q3FY25 Operating EBITDA at ₹171 Mn, margin at 23% Gurugram, January

57%

Jagsonpal Pharmaceuticals announces Q3FY25 and 9MFY25 Results Q3FY25 Revenue at ₹740 Mn, 57% growth over Q3FY24 Q3FY25 Operating EBITDA at ₹171 Mn, margin at 23% Gurugram, January 22, 202

₹171

and 9MFY25 Results Q3FY25 Revenue at ₹740 Mn, 57% growth over Q3FY24 Q3FY25 Operating EBITDA at ₹171 Mn, margin at 23% Gurugram, January 22, 2025: Jagsonpal Pharmaceuticals Limited (BSE: 5077

23%

Q3FY25 Revenue at ₹740 Mn, 57% growth over Q3FY24 Q3FY25 Operating EBITDA at ₹171 Mn, margin at 23% Gurugram, January 22, 2025: Jagsonpal Pharmaceuticals Limited (BSE: 507789, NSE: JAGSNP

23.1%

5 9M FY24 Gr Revenue Operating EBITDA* EBITDA Margin ESOP Cost Business PAT** 740 171 23.1% 13 115 472 60 12.8% 27 40 57% - 1030 bps (52%) - 2,102 482 22.9% 58 316 1,65

12.8%

Operating EBITDA* EBITDA Margin ESOP Cost Business PAT** 740 171 23.1% 13 115 472 60 12.8% 27 40 57% - 1030 bps (52%) - 2,102 482 22.9% 58 316 1,652 314 19.0% 110 189

1030 bps

DA Margin ESOP Cost Business PAT** 740 171 23.1% 13 115 472 60 12.8% 27 40 57% - 1030 bps (52%) - 2,102 482 22.9% 58 316 1,652 314 19.0% 110 189 27% 53% 390 bps (47%) 67

52%

ESOP Cost Business PAT** 740 171 23.1% 13 115 472 60 12.8% 27 40 57% - 1030 bps (52%) - 2,102 482 22.9% 58 316 1,652 314 19.0% 110 189 27% 53% 390 bps (47%) 67% 1.

22.9%

T** 740 171 23.1% 13 115 472 60 12.8% 27 40 57% - 1030 bps (52%) - 2,102 482 22.9% 58 316 1,652 314 19.0% 110 189 27% 53% 390 bps (47%) 67% 1. *Operating EBITDA and E

19.0%

5 472 60 12.8% 27 40 57% - 1030 bps (52%) - 2,102 482 22.9% 58 316 1,652 314 19.0% 110 189 27% 53% 390 bps (47%) 67% 1. *Operating EBITDA and EBITDA margins before ESOP acc

27%

27 40 57% - 1030 bps (52%) - 2,102 482 22.9% 58 316 1,652 314 19.0% 110 189 27% 53% 390 bps (47%) 67% 1. *Operating EBITDA and EBITDA margins before ESOP accounting 2. **Bu

“Mn) Shareholders Funds Tangible Assets Intangibles Right of Use Assets Assets Held for Sale Financial Assets (Cash & Equivalents) Other Non-Current Assets (Net) Lease liabilities Net Working Capital 2,319 8 875 86 0 1,321 23 96 146 1,971 10 894 90 172 934 34 98 133 348 -2 -19 -4 -172 387 -12 -3 13 19 Growth Outlook The 3-Pronged Growth Strategy Outlook – FY25 and Beyond New Product Launch ▪ ▪ Innovation-Driven Growth Launch 4-6 products annually, driving market engagement and revenue.”

“Volume Growth ▪ ▪ Sales Force Empowerment Targeted training boosts medical rep knowledge and productivity FY25 30%+ Revenue Growth ~22% Operating margins (pre-ESOP) Beyond FY25 Price Increases ▪ ▪ Optimizing pricing within 10% regulations for increased Profit-Driven Pricing without NLEM regulation revenue.”

Lean Operations

1

Lean Operations

Asset Light Model Inorganic Growth Powered by Strategic Acquisition 7 Network of Experienced Medical Reps 900+ Well trained and experienced medical representatives across all their therapeutic areas 1.25+ Lk Pharmacies to ensure efficient product delivery 28 States across the nation served through extensive distribution network 1.5+ Lk Prescribers trust, endorsed by healthcare professional's post- acquisition 8 Mother Warehouse Super Stockiest Carry-forward Agents (CFA) Strategic Leap with Yash Pharma JAGSONPAL PHARMACEUTICAL LTD YASH PHARMA LABORATORIES PVT LTD Expertise o 4 Decade of Experience o Field strength of 750+ individuals Innovation o Key Therapeutic areas: Gynecology & Orthopedics Scale o Strong Northern & Eastern presence o Base of 1,00,000 o Robust R&D engine prescribers and pipeline o 17 Stocking Points Expertise o 5 Decade of Experience o Field strength of 250+ individuals Innovation o New segments: Dermatology & Pediatrics Scale o Strong Eastern and Western presence, d